A double blind randomized placebo control trial of levetiracetam in tourette syndrome
Identifieur interne : 003112 ( Main/Exploration ); précédent : 003111; suivant : 003113A double blind randomized placebo control trial of levetiracetam in tourette syndrome
Auteurs : Constance L. Smith-Hicks [États-Unis] ; Dana D. Bridges [États-Unis] ; Nina P. Paynter [États-Unis] ; Harvey S. Singer [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
The objective of this study was to investigate the effectiveness of levetiracetam for the treatment of tics in children with Tourette syndrome (TS). Levetiracetam, an atypical anticonvulsant, has been suggested in open-label protocols to be an effective tic-suppressing agent in individuals with TS. A double blind, randomized, placebo-controlled, cross-over trial was performed to investigate this medication in children with moderate to moderately-severe tics. Subjects received, in a randomized sequence, 4-weeks of levetiracetam (maximum dose 30 mg/kg/day) or placebo, with a 2-week intervening washout period between cycles. Primary outcome measures included two separate scales from the Yale Global Tic Severity Scale; the Total Tic score and the Total overall score. Measures were assessed at baseline, prior to randomization, on Day 28 (end of Phase 1), on Day 42 (baseline for second phase) and on Day 70 (end of Phase 2). Twenty-two subjects (21 boys and 1 girl) with TS, mean age 12.2 ± 2.3 years, range 8 to 16 years, participated. A mild reduction in tics occurred during both the levetiracetam and placebo treatment phases. There was no significant difference between treatments and no evidence of sequence or cross-over effects. In conclusion, Levetiracetam is not more beneficial than placebo in suppressing tics in children with TS.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001538
- to stream PascalFrancis, to step Curation: 001783
- to stream PascalFrancis, to step Checkpoint: 001828
- to stream Main, to step Merge: 004418
- to stream Main, to step Curation: 003112
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A double blind randomized placebo control trial of levetiracetam in tourette syndrome</title><author><name sortKey="Smith Hicks, Constance L" sort="Smith Hicks, Constance L" uniqKey="Smith Hicks C" first="Constance L." last="Smith-Hicks">Constance L. Smith-Hicks</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pediatrics, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bridges, Dana D" sort="Bridges, Dana D" uniqKey="Bridges D" first="Dana D." last="Bridges">Dana D. Bridges</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Paynter, Nina P" sort="Paynter, Nina P" uniqKey="Paynter N" first="Nina P." last="Paynter">Nina P. Paynter</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Epidemiology Johns Hopkins University School of Public Health</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Singer, Harvey S" sort="Singer, Harvey S" uniqKey="Singer H" first="Harvey S." last="Singer">Harvey S. Singer</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pediatrics, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0491124</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0491124 INIST</idno><idno type="RBID">Pascal:07-0491124</idno><idno type="wicri:Area/PascalFrancis/Corpus">001538</idno><idno type="wicri:Area/PascalFrancis/Curation">001783</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001828</idno><idno type="wicri:doubleKey">0885-3185:2007:Smith Hicks C:a:double:blind</idno><idno type="wicri:Area/Main/Merge">004418</idno><idno type="wicri:Area/Main/Curation">003112</idno><idno type="wicri:Area/Main/Exploration">003112</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A double blind randomized placebo control trial of levetiracetam in tourette syndrome</title><author><name sortKey="Smith Hicks, Constance L" sort="Smith Hicks, Constance L" uniqKey="Smith Hicks C" first="Constance L." last="Smith-Hicks">Constance L. Smith-Hicks</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pediatrics, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bridges, Dana D" sort="Bridges, Dana D" uniqKey="Bridges D" first="Dana D." last="Bridges">Dana D. Bridges</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Paynter, Nina P" sort="Paynter, Nina P" uniqKey="Paynter N" first="Nina P." last="Paynter">Nina P. Paynter</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Epidemiology Johns Hopkins University School of Public Health</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Singer, Harvey S" sort="Singer, Harvey S" uniqKey="Singer H" first="Harvey S." last="Singer">Harvey S. Singer</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Pediatrics, Johns Hopkins University School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Gilles de la Tourette syndrome</term><term>Levetiracetam</term><term>Nervous system diseases</term><term>Placebo</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Gilles de la Tourette syndrome</term><term>Placebo</term><term>Lévétiracétam</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to investigate the effectiveness of levetiracetam for the treatment of tics in children with Tourette syndrome (TS). Levetiracetam, an atypical anticonvulsant, has been suggested in open-label protocols to be an effective tic-suppressing agent in individuals with TS. A double blind, randomized, placebo-controlled, cross-over trial was performed to investigate this medication in children with moderate to moderately-severe tics. Subjects received, in a randomized sequence, 4-weeks of levetiracetam (maximum dose 30 mg/kg/day) or placebo, with a 2-week intervening washout period between cycles. Primary outcome measures included two separate scales from the Yale Global Tic Severity Scale; the Total Tic score and the Total overall score. Measures were assessed at baseline, prior to randomization, on Day 28 (end of Phase 1), on Day 42 (baseline for second phase) and on Day 70 (end of Phase 2). Twenty-two subjects (21 boys and 1 girl) with TS, mean age 12.2 ± 2.3 years, range 8 to 16 years, participated. A mild reduction in tics occurred during both the levetiracetam and placebo treatment phases. There was no significant difference between treatments and no evidence of sequence or cross-over effects. In conclusion, Levetiracetam is not more beneficial than placebo in suppressing tics in children with TS.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Smith Hicks, Constance L" sort="Smith Hicks, Constance L" uniqKey="Smith Hicks C" first="Constance L." last="Smith-Hicks">Constance L. Smith-Hicks</name></region><name sortKey="Bridges, Dana D" sort="Bridges, Dana D" uniqKey="Bridges D" first="Dana D." last="Bridges">Dana D. Bridges</name><name sortKey="Paynter, Nina P" sort="Paynter, Nina P" uniqKey="Paynter N" first="Nina P." last="Paynter">Nina P. Paynter</name><name sortKey="Singer, Harvey S" sort="Singer, Harvey S" uniqKey="Singer H" first="Harvey S." last="Singer">Harvey S. Singer</name><name sortKey="Singer, Harvey S" sort="Singer, Harvey S" uniqKey="Singer H" first="Harvey S." last="Singer">Harvey S. Singer</name><name sortKey="Smith Hicks, Constance L" sort="Smith Hicks, Constance L" uniqKey="Smith Hicks C" first="Constance L." last="Smith-Hicks">Constance L. Smith-Hicks</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003112 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003112 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0491124
|texte= A double blind randomized placebo control trial of levetiracetam in tourette syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |